Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Eye (Lond) ; 30(11): 1522, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27315348
2.
Eye (Lond) ; 30(4): 602-7, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26821759

ABSTRACT

PURPOSE: The last article on causes of sight impairment (SI) in England and Wales was for April 2007-March 2008. This report updates these figures for April 2012-March 2013. METHODS: In England and Wales, registration for SI is initiated by completion of a certificate of vision impairment (CVI). The main cause of visual impairment was ascertained for certificates completed April 2012-March 2013. A proportional comparison against April 2007-March 2008 was made. RESULTS: We received 24 009 CVIs of which 10 410 were for severe sight impairment (SSI) and 13 129 were for SI. These numbers were slightly higher than those observed in April 2007-March 2008 (9823 SSI; 12 607 SI). The ratio SI:SSI has remained static with 55% of all certifications being SI. The proportion of certificates without a single main cause has fallen slightly (16.6 to 14%). The proportion of certificates with a main cause of degeneration of the macula and posterior pole (mostly age-related macular degeneration (AMD)) decreased from 58.6 to 50% SSI and from 57.2 to 52.5% SI. Glaucoma remains the second most common cause (11% SSI; 7.6% SI) but hereditary retinal disorders overtook diabetes as third leading cause of SSI. CONCLUSION: AMD is still by far the leading cause of certifications for sight impairment in England and Wales (both SI and SSI). Proportionate changes have been observed since 2008, but it is important to note that a proportionate increase in one condition will impact on others.


Subject(s)
Blindness/epidemiology , Eye Diseases/epidemiology , Vision, Low/epidemiology , Aged , Aged, 80 and over , Blindness/etiology , Diabetic Retinopathy/complications , Diabetic Retinopathy/epidemiology , Disability Evaluation , England/epidemiology , Eye Diseases/complications , Female , Glaucoma/complications , Glaucoma/epidemiology , Humans , Macular Degeneration/complications , Macular Degeneration/epidemiology , Male , Optic Atrophy/complications , Optic Atrophy/epidemiology , Prevalence , Registries/statistics & numerical data , Retinal Diseases/complications , Retinal Diseases/epidemiology , Vision, Low/etiology , Wales/epidemiology
4.
Public Health ; 129(2): 138-42, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25677221

ABSTRACT

OBJECTIVES: To examine variability across England in certification rates for age related macular degeneration (AMD) between 1st April 2011 and 31st March 2012. STUDY DESIGN: Cross-sectional survey. METHODS: An electronic version of the CVI, the ECVI, was used at the Certifications Office, London, to transfer information from paper based certificates into a database. The electronic certifications data set was queried for all certificates completed in England between April 1st 2011 and March 31st 2012 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. Data were explored by type of AMD, visual status, age and sex and then directly standardized rates were computed by English region. RESULTS: The Certifications Office received 23,616 CVIs for England between April 2011 and March 2012, of which 10,481 (44%) were people certified severely sight-impaired (blind) (SSI) and 12,689 (54%) were certified as sight-impaired (partial sight) (SI). The remainder did not have visual status classified. AMD contributed to 11546 causes of certification on the CVI forms during this period, 53% of forms being for geographic atrophy (GA)/dry AMD which is currently mostly untreatable. The median (interquartile) age at certification for AMD was 86 (81, 90) years and women were more commonly certified than men (66%). Considerable variability was seen across English regions, although there was consistency in that GA was the more common form in all areas. CONCLUSIONS: There is considerable regional variability in CVI rates in England, which are not attributable to differences in age or sex. Reasons for such variability need examination yet this should not undermine the value of these data in terms of describing those newly registered with sight impairment due to AMD who are predominantly female and over 85 years of age.


Subject(s)
Blindness/etiology , Macular Degeneration/complications , Aged , Aged, 80 and over , Certification/statistics & numerical data , Cross-Sectional Studies , Databases, Factual , England , Female , Humans , Male
5.
Eye (Lond) ; 28(7): 832-7, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24788009

ABSTRACT

PURPOSE: The purpose of the study was to determine what proportion of new certifications between 1 April 2007 and 31 March 2008 could be attributed to age-related macular degeneration (AMD) and to describe the AMD-certified population in England and Wales. METHODS: An electronic version of the Certificate of Vision Impairment form (CVI), the ECVI, was used at the certifications office to transfer information from the paper-based certificates into a database. The electronic certifications data set was queried for all certificates completed between 1 April 2007 and 31 March 2008 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. The electronic data set was adapted so that a distinction could be made between geographic atrophy (GA) and neovascular AMD (nAMD). RESULTS: The Certifications Office received 23 185 CVIs between April 2007 and March 2008, of whom 9823 (42%) were people registered severely sight impaired (SSI) and 12 607 (52%) were certified as sight impaired (SI). AMD contributed to 13 000 causes of registration on the CVI forms during this period and was the main cause in 11 015 people. In these 11 015 people, GA accounted for 49.3%, nAMD 35.1%, and AMD not specified 15.7%. CONCLUSIONS: The data in this report provide detailed information on CVI registration due to AMD before the widespread adoption of ranibizumab therapy in NHS practice and provide an insight into the burden of vision loss due to AMD at a time of great change in the management of nAMD.


Subject(s)
Blindness/epidemiology , Geographic Atrophy/epidemiology , Registries/statistics & numerical data , Vision, Low/epidemiology , Visually Impaired Persons/statistics & numerical data , Wet Macular Degeneration/epidemiology , Age Distribution , Aged , Aged, 80 and over , Certification/statistics & numerical data , Electronic Health Records , England/epidemiology , Health Surveys , Humans , Middle Aged , Sex Distribution , State Medicine/statistics & numerical data , Visual Acuity/physiology , Wales/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...